JonesResearch analyst Soumit Roy downgraded Surface Oncology (SURF) to Hold from Buy after it was announced that Coherus Biosciences (CHRS) will acquire Surface in a stock-for-stock transaction.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SURF:
- Coherus Biosciences price target lowered to $22 from $24 at Truist
- Surface Oncology downgraded to Neutral from Outperform at Wedbush
- Surface Oncology downgraded to Neutral from Outperform at Baird
- Surface Oncology downgraded to Neutral from Buy at H.C. Wainwright
- Surface Oncology implements 50% workforce reduction
